Shuiying Hu, PhD

Associate Professor

Pharmaceutics and Pharmacology

Research Areas: Cancer, The Division of Pharmaceutics & Pharmacology, Clinical & Pre-Clinical Pharmacology

442 Riffe Building

Professional Interests

The overall goal of Dr. Hu’s research is to evaluate the contribution of uptake transporters, in particular OCT and the OATP1B-type transporters, in the disposition and toxicity of anticancer drugs, with particular emphasis on peripheral neurotoxicity. Her laboratory utilizes multi-level approaches including in vitro, in vivo models, aims to understand the underlying mechanisms that drive the extensive inter-individual pharmacokinetic variability, drug transporter regulation, antitumor efficacy, and drug-drug interaction in response to drug therapy in cancer patients. Another area of research interest is to design of preclinical and clinical studies to evaluate pharmaceutical agents as modulators of side effects associated with tubulin poisons, such as paclitaxel and vincristine.

Education

2004, PhD, Pharmaceutical Sciences, West Virginia University
1999, MS, Chinese Academy of Agricultural Sciences
1995, BS, Shanxi University

Honors

2022, Dean’s Innovation Research Award, OSU College of Pharmacy
2021, American Society of Clinical Pharmacology and Therapeutics (ASCPT) Darrell Abernethy Early Stage Investigator Award
2019, Inaugural Dean's Innovative Research Award, OSU College of Pharmacy

Publications

Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS, Journal of Chromatography B. 2024 May | journal-article. doi: 10.1016/j.jchromb.2024.124106.
Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice., Drug metabolism and disposition: the biological fate of chemicals. 2024 Jan | journal-article. doi: 10.1124/dmd.123.001466.
Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy., JCI insight. 2023 Jul | journal-article. doi: 10.1172/jci.insight.164646.
Data from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity, . 2023 Apr | preprint. doi: 10.1158/2767-9764.c.6550899.v1.
Data from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity, . 2023 Apr | preprint. doi: 10.1158/2767-9764.c.6550899.
Supplementary Tables S1-S2, Figures S1-S8 from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity, . 2023 Apr | preprint. doi: 10.1158/2767-9764.22545309.v1.
Supplementary Tables S1-S2, Figures S1-S8 from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity, . 2023 Apr | preprint. doi: 10.1158/2767-9764.22545309.
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity, Cancer Research Communications. 2022 Nov | journal-article. doi: 10.1158/2767-9764.CRC-22-0172.
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B, Molecules. 2022 Oct | journal-article. doi: 10.3390/molecules27206815.
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities, Pharmaceutics. 2022 Sep | journal-article. doi: 10.3390/pharmaceutics14091933.
Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium, Clinical Pharmacology & Therapeutics. 2022 Sep | journal-article. doi: 10.1002/cpt.2605.
MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia, International Journal of Molecular Sciences. 2022 Aug | journal-article. doi: 10.3390/ijms23158607.
Contribution of membrane transporters to chemotherapy‐induced cardiotoxicity, Basic & Clinical Pharmacology & Toxicology. 2022 Jan | journal-article. doi: 10.1111/bcpt.13635.
In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors, Pharmaceutics. 2021 Nov | journal-article. doi: 10.3390/pharmaceutics13122004.
Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation, Molecules. 2021 Sep | journal-article. doi: 10.3390/molecules26185500.
Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates, Pharmaceutics. 2021 Jun | journal-article. doi: 10.3390/pharmaceutics13060918.
Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies, Journal of Chromatography B. 2021 Apr | journal-article. doi: 10.1016/j.jchromb.2021.122591.
Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy, Cancers. 2021 Feb | journal-article. doi: 10.3390/cancers13040766.
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.12861.
Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1, Frontiers in Pharmacology. 2021 Jan | journal-article. doi: 10.3389/fphar.2021.644342.
Regulation of OATP1B1 function by tyrosine kinase–mediated phosphorylation, Clinical Cancer Research. 2021 Jan | journal-article. doi: 10.1158/1078-0432.CCR-21-0023.
Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.12915.
Targeting OCT3 attenuates doxorubicin-induced cardiac injury, Proceedings of the National Academy of Sciences of the United States of America. 2021 Jan | journal-article. doi: 10.1073/pnas.2020168118.
Targeting drug transporters to prevent chemotherapy-induced peripheral neuropathy, Molecular and Cellular Oncology. 2021 Jan | journal-article. doi: 10.1080/23723556.2020.1838863.
Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy, Nature Communications. 2020 Feb | journal-article. doi: 10.1038/s41467-020-14780-5.
Corrigendum to “Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy” (Materials Science & Engineering C (2019) 102 (113–123), (S0928493118320290), (10.1016/j.msec.2019.03.009)), Materials Science and Engineering C. 2020 Jan | journal-article. doi: 10.1016/j.msec.2019.110326.
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice, Journal of Clinical Investigation. 2020 Jan | journal-article. doi: 10.1172/JCI136796.
Role of OATP2B1 in drug absorption and drug-drug interactions, Drug Metabolism and Disposition. 2020 Jan | journal-article. doi: 10.1124/DMD.119.090316.
Role of SLC transporters in toxicity induced by anticancer drugs, Expert Opinion on Drug Metabolism and Toxicology. 2020 Jan | journal-article. doi: 10.1080/17425255.2020.1755253.
Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1, Clinical Pharmacology and Therapeutics. 2020 Jan | journal-article. doi: 10.1002/cpt.1588.
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML, Nature Communications. 2019 Jan | journal-article. doi: 10.1038/s41467-019-09917-0.
Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study, Journal of Pharmaceutical and Biomedical Analysis. 2019 Jan | journal-article. doi: 10.1016/j.jpba.2019.04.041.
Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy, Materials Science and Engineering C. 2019 Jan | journal-article. doi: 10.1016/j.msec.2019.03.009.
Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice, Clinical and Translational Science. 2019 Jan | journal-article. doi: 10.1111/cts.12630.
Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling, CPT: Pharmacometrics and Systems Pharmacology. 2019 Jan | journal-article. doi: 10.1002/psp4.12472.
Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy, Clinical Cancer Research. 2019 Jan | journal-article. doi: 10.1158/1078-0432.CCR-18-2152.
Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice, Pharmacology Research and Perspectives. 2019 Jan | journal-article. doi: 10.1002/prp2.534.
Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2018 Jan | journal-article. doi: 10.1016/j.jchromb.2018.05.005.
Drug transporters and anthracycline-induced cardiotoxicity, Pharmacogenomics. 2018 Jan | journal-article. doi: 10.2217/pgs-2018-0056.
Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia, SSRN. 2018 Jan | other. doi: 10.2139/ssrn.3155569.
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity, Journal of Clinical Investigation. 2018 Jan | journal-article. doi: 10.1172/JCI96160.
Strategies to Reduce Solute Carrier-Mediated Toxicity, Clinical Pharmacology and Therapeutics. 2018 Jan | journal-article. doi: 10.1002/cpt.1185.
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12480.
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12458.
OCTN1 is a high-affinity carrier of nucleoside analogues, Cancer Research. 2017 Jan | journal-article. doi: 10.1158/0008-5472.CAN-16-2548.
A phosphotyrosine switch regulates organic cation transporters, Nature Communications. 2016 Jan | journal-article. doi: 10.1038/ncomms10880.
ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression, Clinical and Translational Science. 2016 Jan | journal-article. doi: 10.1111/cts.12366.
Evaluation of artemisinins for the treatment of acute myeloid leukemia, Cancer Chemotherapy and Pharmacology. 2016 Jan | journal-article. doi: 10.1007/s00280-016-3038-2.
Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia, Clinical Pharmacology and Therapeutics. 2016 Jan | journal-article. doi: 10.1002/cpt.315.
Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death, Cancer Research. 2016 Jan | journal-article. doi: 10.1158/0008-5472.CAN-15-0694.
Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b, Cancer Research. 2015 Jan | journal-article. doi: 10.1158/0008-5472.CAN-15-0280.
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions, Proceedings of the National Academy of Sciences of the United States of America. 2015 Jan | journal-article. doi: 10.1073/pnas.1424313112.
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1), Clinical Cancer Research. 2014 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-1999.
Influence of drug formulation on OATP1B-mediated transport of paclitaxel, Cancer Research. 2014 Jan | journal-article. doi: 10.1158/0008-5472.CAN-13-3634.
Inhibition of OATP1B1 by tyrosine kinase inhibitors: In vitro-in vivo correlations, British Journal of Cancer. 2014 Jan | journal-article. doi: 10.1038/bjc.2013.811.
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: Influence on antitumor efficacy and systemic clearance, Clinical Pharmacology and Therapeutics. 2013 Jan | journal-article. doi: 10.1038/clpt.2013.145.
Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-0980.
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-3306.
Crenolanib is active against models of drug-resistant FLT3-ITD - Positive acute myeloid leukemia, Blood. 2013 Jan | journal-article. doi: 10.1182/blood-2013-07-513044.
Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics, Molecular Cancer Therapeutics. 2013 Jan | journal-article. doi: 10.1158/1535-7163.MCT-12-0926.
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-1897.
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel, Clinical Cancer Research. 2012 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-0761.
Inhibition of OCTN2-mediated transport of carnitine by etoposide, Molecular Cancer Therapeutics. 2012 Jan | journal-article. doi: 10.1158/1535-7163.MCT-11-0980.
OATP1B1 polymorphism as a determinant of erythromycin disposition, Clinical Pharmacology and Therapeutics. 2012 Jan | journal-article. doi: 10.1038/clpt.2012.106.
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia, Journal of the National Cancer Institute. 2011 Jan | journal-article. doi: 10.1093/jnci/djr107.
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters, Clinical Cancer Research. 2009 Jan | journal-article. doi: 10.1158/1078-0432.CCR-09-0048.
Pharmacogenetic pathway analysis of docetaxel elimination, Clinical Pharmacology and Therapeutics. 2009 Jan | journal-article. doi: 10.1038/clpt.2008.95.
Pharmacokinetic considerations for new targeted therapies, Clinical Pharmacology and Therapeutics. 2009 Jan | journal-article. doi: 10.1038/clpt.2008.242.
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia, Molecular Cancer Therapeutics. 2008 Jan | journal-article. doi: 10.1158/1535-7163.MCT-07-2218.
Interaction of imatinib with human organic ion carriers, Clinical Cancer Research. 2008 Jan | journal-article. doi: 10.1158/1078-0432.CCR-07-4913.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer, Clinical Cancer Research. 2007 Jan | journal-article. doi: 10.1158/1078-0432.CCR-06-1125.
Role of mitochondria in silica-induced apoptosis of alveolar macrophages: Inhibition of apoptosis by rhodamine 6g and N-acetyl-L-cysteine, Journal of Toxicology and Environmental Health - Part A: Current Issues. 2007 Jan | journal-article. doi: 10.1080/15287390701251990.
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant, Clinical Cancer Research. 2007 Jan | journal-article. doi: 10.1158/1078-0432.CCR-06-1753.
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer, International Journal of Cancer. 2006 Jan | journal-article. doi: 10.1002/ijc.22110.
Detection of serum deoxyribonucleic acid methylation markers: A novel diagnostic tool for thyroid cancer, Journal of Clinical Endocrinology and Metabolism. 2006 Jan | journal-article. doi: 10.1210/jc.2005-1810.
Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells, Journal of Immunology. 2006 Jan | journal-article. doi: 10.4049/jimmunol.176.11.6785.
Silica-induced apoptosis in alveolar macrophages: Evidence of in vivo thiol depletion and the activation of mitochondrial pathway, Journal of Toxicology and Environmental Health - Part A: Current Issues. 2006 Jan | journal-article. doi: 10.1080/15287390500361875.
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes, Journal of Clinical Endocrinology and Metabolism. 2005 Jan | journal-article. doi: 10.1210/jc.2004-2353.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors, Journal of Clinical Endocrinology and Metabolism. 2005 Jan | journal-article. doi: 10.1210/jc.2004-2281.
Time-dependent apoptosis of alveolar macrophages from rats exposed to bleomycin: Involvement of TNF receptor 2, Journal of Toxicology and Environmental Health - Part A. 2004 Jan | journal-article. doi: 10.1080/15287390490471569.